CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Pascal Retinal Laser Photocoagulatordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02569892
NCT02569892N/ACompleted
CompareCT.gov

Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

Stanford University·interventional·Posted Oct 7, 2015·Updated Oct 28, 2021

In Brief

A clinical study evaluating Pascal Retinal Laser Photocoagulator for Macular Degeneration and Retinal Drusen. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This is a randomized controlled study of non-damaging photothermal macular grid laser versus sham laser therapy in patients with dry age-related macular degeneration (AMD) and large high-risk drusen. The goal of the study is to determine if this treatment will reduce macular drusen volume and also whether this might improve visual acuity or reduce the risk of conversion to advanced age-related macular degeneration defined as development of choroidal neovascularization or geographic atrophy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration, Retinal Drusen
CountriesUnited States
CollaboratorsBascom Palmer Eye Institute

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 7, 2015
Enrollment StartSep 1, 2016
Primary CompletionFeb 1, 2020
Study CompletionJan 25, 2021
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.7 years ago

Interventions

Pascal Retinal Laser Photocoagulatordevice

Sub-threshold macular laser treatment with Pascal laser Endpoint Management System